Tóm tắt
Đau là biểu hiện phổ biến nhất của lạc nội mạc tử cung. Tuy vậy, tác động lâm sàng của lạc nội mạc tử cung vượt ra ngoài đau vùng chậu, ảnh hưởng sức khoẻ toàn thân, tâm lý và chức năng xã hội, cuối cùng suy giảm chất lượng cuộc sống của bệnh nhân. Do đó, điều quan trọng là đánh giá hiệu quả của phương pháp điều trị đến cuộc sống của người phụ nữ mắc bệnh. Elagolix là một chất đối kháng GnRH, không chỉ hiệu quả trong việc kiểm soát cơn đau vùng chậu mức độ trung bình đến nặng mà còn ảnh hưởng tích cực đến chất lượng cuộc sống của người phụ nữ.
Từ khóa
Tài liệu tham khảo
1. Fuldeore, M. J., & Soliman, A. M. (2017). Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women. Gynecologic and obstetric investigation, 82(5), 453–461. https://doi.org/10.1159/000452660
2. Chapron, C., Marcellin, L., Borghese, B., & Santulli, P. (2019). Rethinking mechanisms, diagnosis and management of endometriosis. Nature reviews. Endocrinology, 15(11), 666–682. https://doi.org/10.1038/s41574-019-0245-z
3. Taylor H. S. (2019). Endometriosis: a complex systemic disease with multiple manifestations. Fertility and sterility, 112(2), 235–236. https://doi.org/10.1016/j.fertnstert.2019.06.006
4. Pessoa de Farias Rodrigues, M., Lima Vilarino, F., de Souza Barbeiro Munhoz, A., da Silva Paiva, L., de Alcantara Sousa, L. V., Zaia, V., & Parente Barbosa, C. (2020). Clinical aspects and the quality of life among women with endometriosis and infertility: a cross-sectional study. BMC women's health, 20(1), 124. https://doi.org/10.1186/s12905-020-00987-7
5. Brosens, J. J., & Gellersen, B. (2012). The uterus under hormonal control--cycling for life. Molecular and cellular endocrinology, 358(2), 145. https://doi.org/10.1016/j.mce.2012.02.023
6. Becker, C. M., Bokor, A., Heikinheimo, O., Horne, A., Jansen, F., Kiesel, L., King, K., Kvaskoff, M., Nap, A., Petersen, K., Saridogan, E., Tomassetti, C., van Hanegem, N., Vulliemoz, N., Vermeulen, N., & ESHRE Endometriosis Guideline Group (2022). ESHRE guideline: endometriosis. Human reproduction open, 2022(2), hoac009. https://doi.org/10.1093/hropen/hoac009
7. Margatho, D., Carvalho, N. M., & Bahamondes, L. (2020). Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 25(2), 133–140. https://doi.org/10.1080/13625187.2020.1725461
8. Carr, B., Giudice, L., Dmowski, W. P., O'Brien, C., Jiang, P., Burke, J., Jimenez, R., Hass, S., Fuldeore, M., & Chwalisz, K. (2013). Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study. Journal of endometriosis and pelvic pain disorders, 5(3), 105–115. https://doi.org/10.5301/je.5000157
9. Diamond, M. P., Carr, B., Dmowski, W. P., Koltun, W., O'Brien, C., Jiang, P., Burke, J., Jimenez, R., Garner, E., & Chwalisz, K. (2014). Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reproductive sciences (Thousand Oaks, Calif.), 21(3), 363–371. https://doi.org/10.1177/1933719113497292
10. Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., Gallagher, J. C., Simon, J. A., Carr, B. R., Dmowski, W. P., Leyland, N., Rowan, J. P., Duan, W. R., Ng, J., Schwefel, B., Thomas, J. W., … Chwalisz, K. (2017). Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. The New England journal of medicine, 377(1), 28–40. https://doi.org/10.1056/NEJMoa1700089
11. Donnez, J., Taylor, R. N., & Taylor, H. S. (2017). Partial suppression of estradiol: a new strategy in endometriosis management?. Fertility and sterility, 107(3), 568–570. https://doi.org/10.1016/j.fertnstert.2017.01.013
12. Acs N, O’Brien C, Jiang P, et al (2015). Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a Phase II, randomized controlled study. J Endometr Pelvic Pain Disord, 7: 56–62. https://doi.org/10.5301/je.5000211
13. Carr, B., Dmowski, W. P., O'Brien, C., Jiang, P., Burke, J., Jimenez, R., Garner, E., & Chwalisz, K. (2014). Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reproductive sciences (Thousand Oaks, Calif.), 21(11), 1341–1351. https://doi.org/10.1177/1933719114549848
14. Surrey, E., Taylor, H. S., Giudice, L., Lessey, B. A., Abrao, M. S., Archer, D. F., Diamond, M. P., Johnson, N. P., Watts, N. B., Gallagher, J. C., Simon, J. A., Carr, B. R., Dmowski, W. P., Leyland, N., Singh, S. S., Rechberger, T., Agarwal, S. K., Duan, W. R., Schwefel, B., Thomas, J. W., … Chwalisz, K. (2018). Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. Obstetrics and gynecology, 132(1), 147–160. https://doi.org/10.1097/AOG.0000000000002675
15. Bourdel, N., Chauvet, P., Billone, V., Douridas, G., Fauconnier, A., Gerbaud, L., & Canis, M. (2019). Systematic review of quality of life measures in patients with endometriosis. PloS one, 14(1), e0208464. https://doi.org/10.1371/journal.pone.0208464
16. Pokrzywinski, R., Soliman, A. M., Chen, J., Snabes, M. C., Taylor, H. S., & Coyne, K. S. (2020). Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials. Journal of women's health (2002), 29(2), 253–261. https://doi.org/10.1089/jwh.2019.7788
17. Orilissa (elagolix) tablets [prescribing information]. North Chicago, IL: AbbVie, Inc., 2018
18. Practice bulletin no. 114: management of endometriosis. (2010). Obstetrics and gynecology, 116(1), 223–236. https://doi.org/10.1097/AOG.0b013e3181e8b073
19. Practice Committee of the American Society for Reproductive Medicine (2014). Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertility and sterility, 101(4), 927–935. https://doi.org/10.1016/j.fertnstert.2014.02.012
20. Wu, D., Hu, M., Hong, L., Hong, S., Ding, W., Min, J., Fang, G., & Guo, W. (2014). Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. Archives of gynecology and obstetrics, 290(3), 513–523. https://doi.org/10.1007/s00404-014-3230-8
21. Archer, D. F., Stewart, E. A., Jain, R. I., Feldman, R. A., Lukes, A. S., North, J. D., Soliman, A. M., Gao, J., Ng, J. W., & Chwalisz, K. (2017). Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertility and sterility, 108(1), 152–160.e4. https://doi.org/10.1016/j.fertnstert.2017.05.006
22. Leyland, N., Estes, S. J., Lessey, B. A., Advincula, A. P., & Taylor, H. S. (2021). A Clinician's Guide to the Treatment of Endometriosis with Elagolix. Journal of women's health (2002), 30(4), 569–578. https://doi.org/10.1089/jwh.2019.8096
23. Elagolix. (2019). In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases.
24. Quaas, A. M., Weedin, E. A., & Hansen, K. R. (2015). On-label and off-label drug use in the treatment of endometriosis. Fertility and sterility, 103(3), 612–625. https://doi.org/10.1016/j.fertnstert.2015.01.006
25. Elagolix. (2019). In Drugs and Lactation Database (LactMed®). National Institute of Child Health and Human Development.
2. Chapron, C., Marcellin, L., Borghese, B., & Santulli, P. (2019). Rethinking mechanisms, diagnosis and management of endometriosis. Nature reviews. Endocrinology, 15(11), 666–682. https://doi.org/10.1038/s41574-019-0245-z
3. Taylor H. S. (2019). Endometriosis: a complex systemic disease with multiple manifestations. Fertility and sterility, 112(2), 235–236. https://doi.org/10.1016/j.fertnstert.2019.06.006
4. Pessoa de Farias Rodrigues, M., Lima Vilarino, F., de Souza Barbeiro Munhoz, A., da Silva Paiva, L., de Alcantara Sousa, L. V., Zaia, V., & Parente Barbosa, C. (2020). Clinical aspects and the quality of life among women with endometriosis and infertility: a cross-sectional study. BMC women's health, 20(1), 124. https://doi.org/10.1186/s12905-020-00987-7
5. Brosens, J. J., & Gellersen, B. (2012). The uterus under hormonal control--cycling for life. Molecular and cellular endocrinology, 358(2), 145. https://doi.org/10.1016/j.mce.2012.02.023
6. Becker, C. M., Bokor, A., Heikinheimo, O., Horne, A., Jansen, F., Kiesel, L., King, K., Kvaskoff, M., Nap, A., Petersen, K., Saridogan, E., Tomassetti, C., van Hanegem, N., Vulliemoz, N., Vermeulen, N., & ESHRE Endometriosis Guideline Group (2022). ESHRE guideline: endometriosis. Human reproduction open, 2022(2), hoac009. https://doi.org/10.1093/hropen/hoac009
7. Margatho, D., Carvalho, N. M., & Bahamondes, L. (2020). Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 25(2), 133–140. https://doi.org/10.1080/13625187.2020.1725461
8. Carr, B., Giudice, L., Dmowski, W. P., O'Brien, C., Jiang, P., Burke, J., Jimenez, R., Hass, S., Fuldeore, M., & Chwalisz, K. (2013). Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study. Journal of endometriosis and pelvic pain disorders, 5(3), 105–115. https://doi.org/10.5301/je.5000157
9. Diamond, M. P., Carr, B., Dmowski, W. P., Koltun, W., O'Brien, C., Jiang, P., Burke, J., Jimenez, R., Garner, E., & Chwalisz, K. (2014). Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reproductive sciences (Thousand Oaks, Calif.), 21(3), 363–371. https://doi.org/10.1177/1933719113497292
10. Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., Gallagher, J. C., Simon, J. A., Carr, B. R., Dmowski, W. P., Leyland, N., Rowan, J. P., Duan, W. R., Ng, J., Schwefel, B., Thomas, J. W., … Chwalisz, K. (2017). Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. The New England journal of medicine, 377(1), 28–40. https://doi.org/10.1056/NEJMoa1700089
11. Donnez, J., Taylor, R. N., & Taylor, H. S. (2017). Partial suppression of estradiol: a new strategy in endometriosis management?. Fertility and sterility, 107(3), 568–570. https://doi.org/10.1016/j.fertnstert.2017.01.013
12. Acs N, O’Brien C, Jiang P, et al (2015). Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: results from a Phase II, randomized controlled study. J Endometr Pelvic Pain Disord, 7: 56–62. https://doi.org/10.5301/je.5000211
13. Carr, B., Dmowski, W. P., O'Brien, C., Jiang, P., Burke, J., Jimenez, R., Garner, E., & Chwalisz, K. (2014). Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reproductive sciences (Thousand Oaks, Calif.), 21(11), 1341–1351. https://doi.org/10.1177/1933719114549848
14. Surrey, E., Taylor, H. S., Giudice, L., Lessey, B. A., Abrao, M. S., Archer, D. F., Diamond, M. P., Johnson, N. P., Watts, N. B., Gallagher, J. C., Simon, J. A., Carr, B. R., Dmowski, W. P., Leyland, N., Singh, S. S., Rechberger, T., Agarwal, S. K., Duan, W. R., Schwefel, B., Thomas, J. W., … Chwalisz, K. (2018). Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. Obstetrics and gynecology, 132(1), 147–160. https://doi.org/10.1097/AOG.0000000000002675
15. Bourdel, N., Chauvet, P., Billone, V., Douridas, G., Fauconnier, A., Gerbaud, L., & Canis, M. (2019). Systematic review of quality of life measures in patients with endometriosis. PloS one, 14(1), e0208464. https://doi.org/10.1371/journal.pone.0208464
16. Pokrzywinski, R., Soliman, A. M., Chen, J., Snabes, M. C., Taylor, H. S., & Coyne, K. S. (2020). Responsiveness Evaluation and Recommendation for Responder Thresholds for Endometriosis Health Profile-30: Analysis of Two Phase III Clinical Trials. Journal of women's health (2002), 29(2), 253–261. https://doi.org/10.1089/jwh.2019.7788
17. Orilissa (elagolix) tablets [prescribing information]. North Chicago, IL: AbbVie, Inc., 2018
18. Practice bulletin no. 114: management of endometriosis. (2010). Obstetrics and gynecology, 116(1), 223–236. https://doi.org/10.1097/AOG.0b013e3181e8b073
19. Practice Committee of the American Society for Reproductive Medicine (2014). Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertility and sterility, 101(4), 927–935. https://doi.org/10.1016/j.fertnstert.2014.02.012
20. Wu, D., Hu, M., Hong, L., Hong, S., Ding, W., Min, J., Fang, G., & Guo, W. (2014). Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. Archives of gynecology and obstetrics, 290(3), 513–523. https://doi.org/10.1007/s00404-014-3230-8
21. Archer, D. F., Stewart, E. A., Jain, R. I., Feldman, R. A., Lukes, A. S., North, J. D., Soliman, A. M., Gao, J., Ng, J. W., & Chwalisz, K. (2017). Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertility and sterility, 108(1), 152–160.e4. https://doi.org/10.1016/j.fertnstert.2017.05.006
22. Leyland, N., Estes, S. J., Lessey, B. A., Advincula, A. P., & Taylor, H. S. (2021). A Clinician's Guide to the Treatment of Endometriosis with Elagolix. Journal of women's health (2002), 30(4), 569–578. https://doi.org/10.1089/jwh.2019.8096
23. Elagolix. (2019). In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases.
24. Quaas, A. M., Weedin, E. A., & Hansen, K. R. (2015). On-label and off-label drug use in the treatment of endometriosis. Fertility and sterility, 103(3), 612–625. https://doi.org/10.1016/j.fertnstert.2015.01.006
25. Elagolix. (2019). In Drugs and Lactation Database (LactMed®). National Institute of Child Health and Human Development.
Công trình này được cấp phép theo Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. .
Download
Dữ liệu downlad không hiện hữu.
Cùng tác giả
- Lê Minh Tâm, Trần Thị Như Quỳnh, Nguyễn Thị Hiệp Tuyết, Có mối liên quan giữa hội chứng chuyển hóa và sức bền tinh trùng? , Tạp chí Phụ sản: Tập 18 Số 1 (2020): Tập 18, Số 1, 2020